Truist Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Negative 71.5%

Neg 71.5% Neu 0% Pos 0%

Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $18.